Abstract 835P
Background
Very old patients usually have various comorbidities, poor performance status and poor frailty. Therefore, as patients get aged, they generally tend to be intolerable to intensive chemotherapy. In Japan, sobuzoxane, which is an oral anticancer drug that inhibits DNA topoisomerase II, was approved in 1994 and has been used for patients with lymphoma. Thus far, we have treated lymphoma patients with an attenuated chemotherapy, oral sobuzoxane and etoposide plus rituximab (R-PVP).
Methods
We retrospectively analysed 30 patients aged 80 and over who were newly diagnosed with diffuse large B-cell lymphoma (DLBCL) and initially treated with R-PVP therapy from 2008 to 2022.
Results
The median age of the patients was 84 years (range, 80-93). The median number of Charlson Comorbidity Index (CCI) was 4 (range, 2-11). Median four doses of both sobuzoxane 400 mg and etoposide 25 mg were orally administered every other day per cycle, and rituximab 375 mg/m2 intravenously once. Patients received a median of six cycles of R-PVP at a four-week interval. With a median follow-up of 26.4 months (range, 5.4-72.9), median progression ‘free survival (PFS) and overall survival (OS) time was 13.9 and 32.0 months, with a 5-year PFS and OS rate of 24% (95% CI, 8-46%) and 28% (95% CI, 10-49%), respectively. The most frequent grade 3 or 4 adverse event was neutropaenia (53%). No deaths were documented due to the toxicities of the treatment. A multivariate logistic regression analysis revealed that serum LDH value of >=1.5x upper limit of normal was the only unfavourable variable for both PFS and OS in R-PVP therapy (PFS: hazard ratio (HR), 5.60; 95% CI, 1.64-19.11; p = 0.006; OS: HR, 4.83; 95% CI, 1.22-19.17; p = 0.025). In a cohort of 20 patients who underwent R-PVP and 25 R-miniCHOP over the past decade, using the Kaplan-Meier method, there were no statistical differences between the groups regarding PFS and OS (median PFS: R-PVP 9.3 months vs. R-miniCHOP 26.4 months, p = 0.307; median OS: R-PVP not reached (NR) vs. R-miniCHOP NR, p = 0.375).
Conclusions
Our findings may suggest that R-PVP therapy is one of safe and effective treatments for a subgroup of patients, i.e. those who have high CCI or low tumour burden, among untreated DLBCL patients aged over 80.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18